asco@alo33:161696 JSONTXT

Background: There are fe reports about patients prognosis depending on primary sites of cancer in palliative care settings. Methods: This study as conducted as a secondary analysis for a large prospective cohort study J-Proval that folloed up patients beteen September 3, 2012 and April 30, 2014 from 58 palliative care institutions across Japan. We obtained data of 2290 patients including those in hospital palliative care teams, palliative care units and home palliative care services. We classified patients into seven categories depending on the primary site of cancer: lung n = 506 , gastro-esophageal n = 317 , colorectal n = 272 , biliary-pancreatic n = 351 , breast n = 119 , urological and gynecological cancer n = 294 , and others n = 431 . The primary endpoint as the actual survival time, measured from the start of registration, by cancer type. The secondary ere the frequency of debilitating complications and end-of life treatment. Results: The median overall survival mOS time as 33 days 95 percent confidence interval [CI], 28 to 38 days , 28 95 percent CI, 23 to 33 , 40 95 percent CI, 33 to 47 , 28 95 percent CI, 24 to 32 , 34 95 percent CI, 26 to 42 , 42 95 percent CI, 31 to 53 and 35 95 percent CI, 29 to 41 for lung, gastro-esophageal, colorectal, biliary-pancreatic, breast, urological and gynecological, and other types of cancers, respectively. mOS as significantly shorter in both gastro-esophageal cancer and biliary-pancreatic cancer after adjustment for patients background. The incidence of delirium as loer in gastro-esophageal cancer 33.4 percent . The incidence of dyspnea as highest in lung 58.9 percent and loest in biliary-pancreatic cancer 30.0 percent . The incidence of appetite loss as highest in gastro-esophageal 88.3 percent . The proportion of patients ho received artificial hydration in the final days of life as performed more frequently in patients ith lung 63.5 percent , gastro-esophageal 60.2 percent , and colorectal 60.2 percent cancers than in the total population. Conclusions: Our results sho a significant difference in the survival time and the frequencies of distressing symptoms and end-of-life treatment depending on the primary site of cancer in palliative care settings.,J Clin Oncol 34, 2016 suppl; abstr 10025 00:00.0,Patient and Survivor Care